FDA Emergency Use Authorization for Gohibic for treatment of critically ill COVID-19 patients
InflaRx N.V. a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, has been granted an Emergency Use Authorization (EUA) by the FDA for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO)